share_log

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

摩根士丹利將Amicus Therapeutics上調至增持,將目標股價提高至20美元
Benzinga ·  2023/12/19 09:09

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and raises the price target from $15 to $20.

摩根士丹利分析師洪傑弗裏將Amicus Therapeutics(納斯達克股票代碼:FOLD)從等權重上調至增持,並將目標股價從15美元上調至20美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論